GLP-1 Receptor Agonists Directly Boost Human Heart Muscle Contraction
Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of drugs widely prescribed for type 2 diabetes and obesity, known for their beneficial cardiovascular outcomes, including reduced risk of heart failure. While their systemic effects on the heart are well-documented, the direct impact of GLP-1 RAs on the contractile function of human heart muscle has remained less clear. This study aimed to elucidate these acute, direct effects on isolated human cardiac tissue.
Study Design
Results
Both liraglutide and semaglutide acutely and significantly increased the force of contraction in human atrial trabeculae in a concentration-dependent manner. Liraglutide induced a maximum increase in contractile force to 143% ± 12% of baseline at 10 µM, a statistically significant improvement compared to control (p<0.01). Similarly, semaglutide enhanced contractile force to 138% ± 10% of baseline at 10 µM, also showing high significance (p<0.01). The positive inotropic effect (increased contractility) observed with both liraglutide and semaglutide was significantly attenuated by the PKA inhibitor KT5720 (p<0.05), strongly suggesting involvement of the cAMP/PKA signaling pathway. In contrast, the sGC inhibitor ODQ had no significant impact on the contractile response, indicating that the cGMP pathway is not primarily involved in these acute effects.
Why It Matters
This study provides compelling direct evidence that GLP-1 RAs acutely enhance the contractility of human heart muscle, independent of their systemic metabolic effects. This direct positive inotropic effect could be a crucial mechanism contributing to the observed cardiovascular benefits of GLP-1 RAs in patients, particularly those with heart failure. These findings suggest a potential for GLP-1 RAs to directly improve cardiac function in specific heart conditions, potentially leading to new clinical applications and therapeutic strategies. Further research, including in vivo human studies and potentially Phase II clinical trials, is warranted to confirm these direct cardiac effects within a living organism.